Chloe Thio

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Hepatitis B virus treatment in HIV-infected patients
    Chloe L Thio
    The Johns Hopkins University, Baltimore, MD, USA
    Top HIV Med 14:170-5. 2006
  2. pmc Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort
    Chloe L Thio
    Johns Hopkins University, Baltimore, Maryland 21205, USA
    AIDS 27:191-201. 2013
  3. ncbi request reprint Racial differences in HLA class II associations with hepatitis C virus outcomes
    C L Thio
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231 1001, USA
    J Infect Dis 184:16-21. 2001
  4. pmc Host genetic factors and antiviral immune responses to hepatitis C virus
    Chloe L Thio
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA
    Clin Liver Dis 12:713-26, xi. 2008
  5. doi request reprint Hepatitis B and human immunodeficiency virus coinfection
    Chloe L Thio
    Johns Hopkins University, Division of Infectious Diseases, Baltimore, MD 21205, USA
    Hepatology 49:S138-45. 2009
  6. ncbi request reprint Treatment of HIV/HBV coinfection: clinical and virologic issues
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, 424 North Bond St, Baltimore, MD 21231, USA
    AIDS Rev 9:40-53. 2007
  7. pmc Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy
    Chloe L Thio
    Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 15:487-91. 2010
  8. ncbi request reprint Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients
    Chloe L Thio
    Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 12:H25-31. 2007
  9. ncbi request reprint Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Clin Infect Dis 41:1035-40. 2005
  10. pmc Mannose binding lectin genotypes influence recovery from hepatitis B virus infection
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Virol 79:9192-6. 2005

Detail Information

Publications47

  1. ncbi request reprint Hepatitis B virus treatment in HIV-infected patients
    Chloe L Thio
    The Johns Hopkins University, Baltimore, MD, USA
    Top HIV Med 14:170-5. 2006
    ..Thio, MD, at the 9th Annual Ryan White CARE Act Update in Washington, DC. The original presentation is available as a Webcast at www.iasusa.org...
  2. pmc Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort
    Chloe L Thio
    Johns Hopkins University, Baltimore, Maryland 21205, USA
    AIDS 27:191-201. 2013
    ..To understand the HIV-hepatitis B virus (HBV) epidemic from a global perspective by clinically and virologically characterizing these viruses at the time of antiretroviral therapy (ART) initiation in a multinational cohort...
  3. ncbi request reprint Racial differences in HLA class II associations with hepatitis C virus outcomes
    C L Thio
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231 1001, USA
    J Infect Dis 184:16-21. 2001
    ..36; 95% CI, 1.23-4.52) and its DQB1*0201 haplotype. These results support a role for class II alleles in the immune response to HCV and underscore the importance of studying genetic associations in an ethnically diverse cohort...
  4. pmc Host genetic factors and antiviral immune responses to hepatitis C virus
    Chloe L Thio
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA
    Clin Liver Dis 12:713-26, xi. 2008
    ..Results of some of these studies complement knowledge gained from immunology studies, and others offer new insights into HCV biology. This review summarizes published studies on variation in immune-response genes and HCV outcomes...
  5. doi request reprint Hepatitis B and human immunodeficiency virus coinfection
    Chloe L Thio
    Johns Hopkins University, Division of Infectious Diseases, Baltimore, MD 21205, USA
    Hepatology 49:S138-45. 2009
    ..Further research is also needed to determine the mechanism(s) for the increased liver disease progression and optimal treatment goals...
  6. ncbi request reprint Treatment of HIV/HBV coinfection: clinical and virologic issues
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, 424 North Bond St, Baltimore, MD 21231, USA
    AIDS Rev 9:40-53. 2007
    ..Effective antiviral treatment can precipitate immune reconstitution disease resulting in serious hepatic flare and precipitating liver decompensation. Clearly, more data are needed to more effectively treat HIV/HBV coinfection...
  7. pmc Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy
    Chloe L Thio
    Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 15:487-91. 2010
    ..This review will discuss studies of drug-resistant HBV in HIV-infected persons including drug-resistant mutations that have been identified and clinical sequelae of these mutations...
  8. ncbi request reprint Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients
    Chloe L Thio
    Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 12:H25-31. 2007
    ..In addition, noninvasive methods for classifying liver disease stage are discussed, as are special considerations that are needed for individuals coinfected with HIV...
  9. ncbi request reprint Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Clin Infect Dis 41:1035-40. 2005
  10. pmc Mannose binding lectin genotypes influence recovery from hepatitis B virus infection
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Virol 79:9192-6. 2005
    ..76; 95% CI, 1.02 to 3.01; P = 0.04). These data are consistent with the hypothesis that functional MBL plays a central role in the pathogenesis of acute hepatitis B...
  11. pmc HLA-Cw*04 and hepatitis C virus persistence
    Chloe L Thio
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, USA
    J Virol 76:4792-7. 2002
    ..Further investigation is needed to understand the relationship between class I alleles and HCV clearance...
  12. ncbi request reprint HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
    Chloe L Thio
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet 360:1921-6. 2002
    ..Our aim was to examine liver-related mortality among people at risk for HIV-1 and HBV infections...
  13. ncbi request reprint An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection
    C L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
    Genes Immun 5:294-300. 2004
    ..Further study of this polymorphism and haplotype is needed to understand these associations and the role of TNF-alpha in determining outcomes of HCV infection...
  14. ncbi request reprint Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment
    Chloe L Thio
    Assistant Professor of Medicine, Johns Hopkins University, Baltimore, Maryland 21231 1001, USA
    Semin Liver Dis 23:125-36. 2003
    ..As new drugs currently in clinical trials become available, therapy for chronic hepatitis B will enter the promising era of combination therapy...
  15. ncbi request reprint Changes in hepatitis B virus DNA levels with acute HIV infection
    Chloe L Thio
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 38:1024-9. 2004
    ..Acute HIV infection is not consistently associated with an increased blood HBV DNA level. Additional research is needed to understand the mechanism for the unexpected reductions in HBV DNA levels associated with acute HIV infection...
  16. pmc Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection
    Chloe L Thio
    Department of Medicine, Johns Hopkins Medical Institutions, 1503 E Jefferson Street, Baltimore, MD 21231, USA
    J Virol 78:11258-62. 2004
    ..32, P = 0.04). These data suggest that CTLA4 influences recovery from HBV infection, which is consistent with the emerging role of T regulatory cells in the pathogenesis of disease...
  17. pmc Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection
    Chloe L Thio
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Virol 77:12083-7. 2003
    ..The associations with class I alleles are consistent with a previously implicated role for CD8-mediated cytolytic-T-cell response in determining the outcome of an acute HBV infection...
  18. pmc The HBV drug entecavir - effects on HIV-1 replication and resistance
    Moira A McMahon
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    N Engl J Med 356:2614-21. 2007
    ..Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens...
  19. pmc IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection
    Maureen P Martin
    Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC Frederick, NCI Frederick, Frederick, Maryland, USA
    J Infect Dis 202:1749-53. 2010
    ..99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV...
  20. ncbi request reprint Management of chronic hepatitis B in the HIV-infected patient
    Chloe L Thio
    Johns Hopkins University, Baltimore, Maryland, USA
    AIDS Read 14:122-9, 133, 136-7. 2004
    ..It is anticipated that we are entering a period of combination therapy for chronic hepatitis B, but the ideal combination needs to be elucidated...
  21. pmc Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance
    Ping An
    Laboratory of Genomic Diversity, Science Applications International Corportation Frederick, MD, USA
    J Infect Dis 198:1159-65. 2008
    ..77-11.6]) was also strongly associated with viral clearance. No association was found among those with hemophilia. These results suggest that IL18 promoter polymorphism may affect the outcome of HCV infection in certain groups...
  22. doi request reprint Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study
    Gypsyamber D'Souza
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 48:491-9. 2008
    ..To examine the incidence and risk factors for anal cancer in a multicenter cohort of human immunodeficiency virus (HIV) positive and HIV-negative men who have sex with men followed between 1984 and 2006 (Multicenter AIDS Cohort Study)...
  23. pmc Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome
    Ann L Truelove
    Laboratory of Genomic Diversity, National Cancer Institute, Frederick, MD, USA
    Int J Immunogenet 35:255-64. 2008
    ..01-0.04). These results suggest that IL10 and IL20 gene variants influence HBV infection outcome and encourage the pursuit of further studies of these cytokines in HBV pathogenesis...
  24. doi request reprint Tenofovir for the treatment of hepatitis B virus
    Alice M Jenh
    Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Pharmacotherapy 29:1212-27. 2009
    ..In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir...
  25. pmc Hepatitis B and long-term HIV outcomes in coinfected HAART recipients
    Christopher J Hoffmann
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    AIDS 23:1881-9. 2009
    ..Chronic hepatitis B (CH-B) is common among HIV-infected individuals and increases liver-related mortality in the absence of HAART. The impact of CH-B on long-term HAART outcomes has not been fully characterized...
  26. pmc Liver disease in the HIV-infected individual
    Jennifer C Price
    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Clin Gastroenterol Hepatol 8:1002-12. 2010
    ....
  27. pmc IL28B and the control of hepatitis C virus infection
    Ashwin Balagopal
    Division of Infectious Diseases, Center for Viral Hepatitis, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Gastroenterology 139:1865-76. 2010
    ..We review the genetic studies that uncovered the association between IL28B and HCV clearance, the biology of IFN-λ3, the clinical implications of the genetic association, and areas of future research...
  28. pmc Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelines
    Stephen A Berry
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287 2100, USA
    Sex Transm Infect 86:481-4. 2010
    ..This study determined GC/CT testing rates in a clinical HIV cohort before and after 2003 when the US Centers for Disease Control and Prevention issued guidelines for GC/CT screening...
  29. ncbi request reprint Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B
    Christopher J Hoffmann
    Aurum Institute for Health Research, Johannesburg, South Africa
    AIDS 21:1301-8. 2007
    ..Hepatotoxicity is a significant complication of antiretroviral therapy (ART). We assessed the incidence of and risk factors for hepatotoxicity among HIV-infected individuals on ART in South Africa...
  30. pmc Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events
    Christopher J Hoffmann
    Aurum Institute for Health Research, Johannesburg, South Africa
    AIDS 22:67-74. 2008
    ..To describe the safety and tolerability of zidovudine, lamivudine, and efavirenz in a low-income setting...
  31. pmc Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    J Virol 81:441-5. 2007
    ....
  32. pmc Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
    David L Thomas
    Johns Hopkins University, Division of Infectious Diseases, Baltimore, Maryland 21205, USA
    Nature 461:798-801. 2009
    ..To our knowledge, this is the strongest and most significant genetic effect associated with natural clearance of HCV, and these results implicate a primary role for IL28B in resolution of HCV infection...
  33. ncbi request reprint Clinical implications of HIV and hepatitis B co-infection in Asia and Africa
    Christopher J Hoffmann
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Lancet Infect Dis 7:402-9. 2007
    ..This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted...
  34. pmc Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus
    Timothy L Mosbruger
    Johns Hopkins University, Baltimore, MD, USA
    J Infect Dis 201:1371-80. 2010
    ..In this large-scale analysis of 1426 genotyped SNPs in 112 candidate genes, we identified 4 gene regions that are likely candidates for a role in HCV clearance or persistence in both African Americans and European Americans...
  35. pmc Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    J Immunol 181:7944-7. 2008
    ....
  36. pmc Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus
    Ned Sacktor
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Neurovirol 16:335-41. 2010
    ..Mild neurocognitive changes over time among older HIV+ individuals are likely to reflect age associated pathophysiological mechanisms including cerebrovascular risk factors...
  37. pmc High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda
    Lara Stabinski
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Antivir Ther 16:405-11. 2011
    ..Liver disease is a leading cause of mortality among HIV-infected persons in the United States and Europe. However, data regarding the effects of HIV and antiretroviral therapy (ART) on liver disease in Africa are sparse...
  38. ncbi request reprint HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection
    Salim I Khakoo
    Liver Group, Division of Infection, Inflammation, and Repair, Southampton University, Southampton 5016 6YD, UK
    Science 305:872-4. 2004
    ..The data strongly suggest that inhibitory NK cell interactions are important in determining antiviral immunity and that diminished inhibitory responses confer protection against HCV...
  39. ncbi request reprint Treatment of chronic hepatitis B in the HIV-infected patient
    Chloe L Thio
    Hopkins HIV Rep 15:9, 12. 2003
  40. ncbi request reprint Association of CTLA4 polymorphism with regulatory T cell frequency
    Sowsan F Atabani
    Division of Molecular Immunology, Cincinnati Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Eur J Immunol 35:2157-62. 2005
    ..These data implicate CTLA4 in regulatory T cell development, and provide a mechanism to account for the link between polymorphisms at this locus and the biological outcome of adaptive immune responses to self and to pathogens...
  41. pmc A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection
    Ying Huang
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:985-90. 2007
    ....
  42. ncbi request reprint Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
    Chloe L Thio
    J Hepatol 44:1-3. 2006
  43. ncbi request reprint Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...
  44. ncbi request reprint Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 20:863-70. 2006
    ..Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy...
  45. ncbi request reprint Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals
    Peter A Revill
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
    AIDS 21:1701-10. 2007
    ..To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy...
  46. ncbi request reprint Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase
    Robert A Domaoal
    Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520 8066, USA
    J Biol Chem 283:5452-9. 2008
    ..This study has important therapeutic implications as it establishes ETV as an inhibitor for HIV-1 RT and illustrates the mechanism of resistance by the M184V mutant...
  47. pmc The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients
    Joe Sasadeusz
    The Alfred Hospital, Melbourne, Victoria, Australia
    AIDS 22:947-55. 2008
    ....

Research Grants11

  1. Hepatitis B treatment and HIV Infection in resources limited settings
    Chloe Thio; Fiscal Year: 2007
    ..This proposal has a high likelihood for success given the investigative team's experience, the randomized clinical trial design, and the nesting in an existing study. ..
  2. Liver Disease and HIV-HBV Coinfection in the HAART era
    Chloe Thio; Fiscal Year: 2007
    ..Given the experience of the investigative team and the well-characterized cohorts involved, the results from this proposal will yield insights into the management of HIV-HBV co-infected patients. ..
  3. Hepatitis B treatment and HIV Infection in resources limited settings
    Chloe L Thio; Fiscal Year: 2010
    ..This proposal has a high likelihood for success given the investigative team's experience, the randomized clinical trial design, and the nesting in an existing study. ..